title: Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis.
abstract: Intravenous cyclophosphamide (IVC) in combination with steroids is standard therapy for Lupus nephritis. Reduction of autoantibodies and circulating immune complexes can be used in the treatment of autoimmune diseases. The aim of the present study was to compare the effects of IVC pulse therapy and double-filtration plasmapheresis (DFPP) on proteinuria and urinary excretion of podocytes in adult patients with diffuse proliferative Lupus nephritis (DPLN). Twenty patients were randomly assigned to two groups. Group A (n = 10) was treated with IVC (0.75 - 1.0 g/m2 body surface area) pulse therapy, given as boluses once a month for 6 consecutive months, combined with oral corticosteroid (up to 1 mg/kg/day) administration. Group B (n = 10) was treated with a combination of DFPP (performed 1-2 times weekly) and corticosteroid (up to I mg/kg/ day). The total average number of treatments was 8.4 and the therapeutic efficacies were evaluated after 6 months. Twenty healthy individuals participated as a control group. Urinary podocytes were examined by immunofluorescence with monoclonal antibodies against podocalyxin. Both Group A and Group B reduced proteinuria (p < 0.001) as well as the number of urinary podocytes (p < 0.001). Differences between the 2 treatment outcomes were not statistically significant. Cyclophosphamide pulse therapy and DFPP may be similarly effective in the treatment of podocyte injury in patients with DPLN.
authors.affiliation: Department of Medicine, Misato Junshin Hospital, Saitama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: C
authors.initials: C
authors.lastname: Ushiyama
authors.forename: M
authors.initials: M
authors.lastname: Hara
authors.forename: S
authors.initials: S
authors.lastname: Osada
authors.forename: K
authors.initials: K
authors.lastname: Ugai
authors.forename: N
authors.initials: N
authors.lastname: Shimada
authors.forename: K
authors.initials: K
authors.lastname: Hayashi
authors.forename: I
authors.initials: I
authors.lastname: Ebihara
authors.forename: H
authors.initials: H
authors.lastname: Koide
mesh_terms: D000328:Adult; D002452:Cell Count; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007275:Injections, Intravenous; D007678:Kidney Glomerulus / Q000473:pathology*; D008181:Lupus Nephritis / Q000628:therapy* / Q000652:urine; D008297:Male; D010956:Plasmapheresis; D011507:Proteinuria; D014556:Urine / Q000166:cytology*
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide